GA 20 mg/mL
GA-MS-303
Phase 3 small_molecule completed
Quick answer
GA 20 mg/mL for Relapsing-Remitting Multiple Sclerosis is a Phase 3 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Teva Pharma GmbH
- Indication
- Relapsing-Remitting Multiple Sclerosis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed